Publications by authors named "W Brumskine"
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study.
PLOS Glob Public Health
December 2024
Limited studies have been conducted on the safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income settings, especially those with high-HIV prevalence., The Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.
View Article and Find Full Text PDFBackground: There are gaps in uptake of, adherence to, and persistence in the use of preexposure prophylaxis for human immunodeficiency virus (HIV) prevention among cisgender women.
Methods: We conducted a phase 3, double-blind, randomized, controlled trial involving adolescent girls and young women in South Africa and Uganda. Participants were assigned in a 2:2:1 ratio to receive subcutaneous lenacapavir every 26 weeks, daily oral emtricitabine-tenofovir alafenamide (F/TAF), or daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF; active control); all participants also received the alternate subcutaneous or oral placebo.
Article Synopsis
- - Adolescents in sub-Saharan Africa are highly vulnerable to HIV, STIs, and unintended pregnancies, prompting a study in Rustenburg, South Africa that followed 223 participants aged 12-19 to better understand their unique healthcare needs over 12 months.
- - The study revealed that among sexually active participants, the incidences of HIV and STIs were notably higher for females, with significant statistics showing 1.5 HIV cases, 15.7 chlamydia cases, and 15.0 pregnancies per 100 person-years at risk.
- - Some participants, particularly younger ones, experienced unexpected pregnancies and STIs even without reported sexual activity; the study also faced disruptions due to the COVID-19 pandemic, requiring
Background: To produce quality data that informs valid clinical trial results and withstands regulatory inspection, trial sites should adhere to many complex and dynamic requirements. Understanding non-conformance to requirements informs the emerging field of improvement science. We describe protocol deviations in South Africa's largest HIV vaccine efficacy trial.
View Article and Find Full Text PDFBackground: The ALVAC/gp120 + MF59 vaccines in the HIV Vaccine Trials Network (HVTN) 702 efficacy trial did not prevent human immunodeficiency virus-1 (HIV-1) acquisition. Vaccine-matched immunological endpoints that were correlates of HIV-1 acquisition risk in RV144 were measured in HVTN 702 and evaluated as correlates of HIV-1 acquisition.
Methods: Among 1893 HVTN 702 female vaccinees, 60 HIV-1-seropositive cases and 60 matched seronegative noncases were sampled.